Ocugen (OCGN) Cash from Operations Growth (3y) (2017 - 2026)

Ocugen (OCGN) Cash from Operations Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -7.60%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Ocugen 399.60 Mn 399.60 Mn - -6.11%

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.11%
Dec 31, 2025 6.20%
Sep 30, 2025 3.34%
Jun 30, 2025 8.04%
Mar 31, 2025 -8.71%
Dec 31, 2024 6.80%
Sep 30, 2024 -11.86%
Jun 30, 2024 23.11%
Mar 31, 2024 -26.11%
Dec 31, 2023 -38.19%
Sep 30, 2023 -72.87%
Jun 30, 2023 -82.64%
Mar 31, 2023 -57.30%
Dec 31, 2022 -24.60%
Sep 30, 2022 -89.00%
Jun 30, 2022 -60.07%
Mar 31, 2022 -78.09%
Dec 31, 2021 -66.26%
Sep 30, 2021 -5.20%
Jun 30, 2021 -61.11%